Midcap Financial Investment Stock Earnings Reports

Key points for investors: MidCap Financial Investment Corporation (MFIC) substantially reduced its exposure to Merx: following post-quarter sales and insurance recoveries, Merx is expected to repay ~ $90 million to MFIC in Q3 2025 (about half of MFIC’s June carrying value), lowering MFIC’s pro forma Merx exposure to ~ $95 million (~2.8% of the portfolio). Management expects the Merx transactions and recoveries to have a positive NAV impact in the high-single-digit per‑share range and expects redeploying the initial $90 million to add roughly $0.06 of annual net investment income (with remaining Merx value expected to add another ~ $0.06 when realized). Financial results and capital: NII was $0.39 per share in Q2 (annualized ROE on NII 10.5%), GAAP EPS was $0.19, and NAV per share was $14.75 (down 1.2% QoQ). Portfolio fair value was $3.33 billion across 249 companies; 92% direct origination, 99% first lien, and ~90% sponsor‑backed. Q2 new commitments totaled $262 million across 29 transactions (weighted‑average spread ~538 bps; excluding outliers ~526 bps) with weighted average net leverage on new commitments ~4.0x. Nonaccruals rose to 2% of the portfolio (company‑specific issues). Balance sheet and liability actions: total principal debt outstanding ~$2.05 billion, net assets ~$1.3 billion, net leverage 1.44x (pro forma 1.37x including the Merx repayment). Management plans to reprice/upsize its first CLO this fall if market conditions permit. Corporate changes: Kenny Seifert appointed CFO effective June 30, 2025; Greg Hunt will advise through December 2025; Executive Chairman Howard Widra plans to retire from Apollo end of 2026. Outlook / risks: management sees improving market sentiment and a potentially more active M&A pipeline in H2 2025 but notes primary market spreads have compressed (primary pricing in low‑5s to mid/low‑4s) and some company‑specific credit losses drove an ~$18.3 million pre‑tax net loss in the quarter. Management expects redeployment of Merx proceeds to be accretive to earnings and to strengthen dividend coverage (Board declared a $0.38 quarterly dividend).